Trinity Capital Inc. Provides $68.75 Million in Growth Capital to CMR Surgical

Rhea-AI Summary

Trinity Capital Inc. (NASDAQ: TRIN) has committed up to $68.75 million in growth capital to CMR Surgical, as part of the company's recent $200+ million financing round. CMR Surgical, based in Cambridge, UK, develops the Versius Surgical Robotic System, a soft-tissue surgical robot recently granted FDA marketing authorization for Cholecystectomy procedures in the United States.

The funding will support CMR Surgical's operational scaling and commercial expansion globally, with a particular focus on the U.S. market launch. The company aims to make robotic minimal access surgery more accessible and affordable for hospitals and surgical teams worldwide.

Positive

• Secured significant funding commitment of $68.75M from Trinity Capital
• Part of larger $200M+ financing round indicating strong investor interest
• Recent FDA marketing authorization for Versius system in U.S. market
• Clear path for commercial expansion into the lucrative U.S. market

Negative

• None.

PHOENIX, April 2, 2025 /PRNewswire/ -- Trinity Capital Inc. (NASDAQ: TRIN) (the "Company"), a leading alternative asset manager, today announced the commitment of up to $68.75 million in growth capital to CMR Surgical, a global medical devices company dedicated to transforming surgery with the Versius Surgical Robotic System (Versius), a versatile and adaptable soft-tissue surgical robot. The investment forms part of the company's recently closed financing round of more than $200 million.

Headquartered in Cambridge, United Kingdom, CMR Surgical is dedicated to collaborating with surgical teams and hospital partners to make robotic minimal access surgery universally accessible and affordable. The company was recently granted marketing authorization by the U.S. Food and Drug Administration (FDA) for the use of Versius in Cholecystectomy, paving the way for the introduction of its next generation, digitally driven surgical robot in the United States.

"CMR Surgical's innovative approach and consistent progress in surgical robotics demonstrate a promising trajectory in the medtech sector, as they empower hospitals and surgeons with greater access to next-generation technology," said Rob Lake, Senior Managing Director, Life Sciences at Trinity Capital.

This growth capital will enable CMR Surgical to continue to scale operations and accelerate the commercial expansion of their Versius Surgical Robotic System to more hospitals around the world – with a major focus on launching Versius in the United States.

Massimiliano Colella, Chief Executive Officer at CMR Surgical, said: "CMR is a competitive, well-established company with a transformative product providing clear clinical value. We are now at a pivotal stage, poised to capitalize on significant opportunities for market expansion, including in the U.S., while continuing to penetrate deeper into existing markets. I would like to thank Trinity Capital for their support and for their belief in our strategic vision of making robotic assisted surgery accessible to all patients who need it."

About Trinity Capital Inc.

Trinity Capital Inc. (Nasdaq: TRIN) is an international alternative asset manager, aiming to provide investors with stable and consistent returns through access to the private credit market. We source, vet, and invest in dynamic privately funded growth-oriented companies, giving our investors access to a strong and diversified portfolio. With distinct business verticals, Trinity Capital stands as a trusted partner for innovative companies seeking tailored growth capital solutions. Headquartered in Phoenix, Arizona, the firm has an international footprint, supported by a dedicated team of strategically located investment professionals. For more information, visit the company's website at trinitycapital.com and stay connected by following us on LinkedIn and X (formerly Twitter).

About CMR Surgical

CMR Surgical (CMR) is a global medical devices company dedicated to transforming surgery with Versius, a next-generation surgical robot. Headquartered in Cambridge, United Kingdom, CMR is committed to working with surgeons, surgical teams, and hospital partners, to provide an optimal tool to make robotic minimal access surgery universally accessible and affordable. With Versius, CMR's mission is to redefine the surgical robotics market with practical, innovative technology and data that can improve surgical care. Founded in 2014, CMR Surgical is a private limited company backed by an international shareholder base.

View original content to download multimedia:https://www.prnewswire.com/news-releases/trinity-capital-inc-provides-68-75-million-in-growth-capital-to-cmr-surgical-302418970.html

SOURCE Trinity Capital Inc.

FAQ

How much funding did Trinity Capital (TRIN) commit to CMR Surgical in April 2025?

Trinity Capital committed up to $68.75 million in growth capital to CMR Surgical, as part of a larger $200+ million financing round.

What recent FDA approval did CMR Surgical receive for its Versius system?

CMR Surgical received FDA marketing authorization for the use of Versius in Cholecystectomy procedures in the United States.

What is the primary use of the Trinity Capital (TRIN) funding for CMR Surgical?

The funding will be used to scale operations and accelerate commercial expansion of the Versius Surgical Robotic System globally, with focus on U.S. market launch.

What type of medical device does CMR Surgical develop?

CMR Surgical develops the Versius Surgical Robotic System, a versatile and adaptable soft-tissue surgical robot.